First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

BACKGROUND: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the efficacy and safety of bevacizumab plus XELOX, followed by bevacizumab plus capecita...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Feliu, J, Salud, A, Safont, M J, García-Girón, C, Aparicio, J, Vera, R, Serra, O, Casado, E, Jorge, M, Escudero, P, Bosch, C, Bohn, U, Pérez-Carrión, R, Carmona, A, Martínez-Marín, V, Maurel, J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102952/
https://ncbi.nlm.nih.gov/pubmed/24946000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados